Pensionfund Sabic Acquires New Position in AbbVie Inc. $ABBV

Pensionfund Sabic acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, HoldingsChannel reports. The firm acquired 17,600 shares of the company’s stock, valued at approximately $4,021,000. AbbVie comprises 1.1% of Pensionfund Sabic’s holdings, making the stock its 19th largest position.

A number of other large investors have also recently bought and sold shares of ABBV. Vanguard Group Inc. raised its position in shares of AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after purchasing an additional 448,554 shares during the period. Norges Bank acquired a new position in AbbVie during the 2nd quarter valued at approximately $4,288,200,000. Legal & General Group Plc boosted its position in AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP grew its stake in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the last quarter. Finally, Amundi grew its stake in AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase‑1 obesity data for ABBV‑295: AbbVie reported dose‑dependent, meaningful weight loss from ABBV‑295 (a long‑acting amylin analog), marking the company’s formal entry into the anti‑obesity market and diversifying revenue beyond immunology and oncology — a potentially material long‑term growth driver if later‑stage trials succeed. AbbVie’s ABBV-295 Obesity Data Opens New Non Incretin Opportunity
• Positive Sentiment: Multi‑year MLB partnership expands “Striking Out Cancer” nationally: AbbVie was named the Official Pharmaceutical Partner of Major League Baseball, amplifying its cancer‑support initiative, broadening brand reach and CSR impact (each MLB strikeout triggers donations to Stand Up To Cancer). This raises AbbVie’s consumer visibility and may help patient‑facing positioning. AbbVie Named Official Pharmaceutical Partner of Major League Baseball (PR Newswire) MLB: AbbVie named official pharmaceutical partner
• Positive Sentiment: Recent fundamentals and legal risk reduction support the story: AbbVie beat top‑line estimates in its latest quarter, raised FY‑2026 guidance, and a Bloomberg Law report shows the company prevailed in a worker’s suit over family‑medical‑history queries — reducing a potential legal overhang. These items support earnings visibility and dividend stability. AbbVie to sponsor leading US baseball league AbbVie beats worker’s suit (Bloomberg Law)
• Neutral Sentiment: Positive media/analyst commentary on valuation: Several outlets (The Motley Fool, Kalkine) highlight AbbVie’s dividend, revenue growth and argue the stock looks attractively valued, which may support longer‑term investor interest but is not an immediate catalyst. Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now AbbVie Shares Rise on Revenue Growth (Kalkine)
• Negative Sentiment: Valuation and technical/financial quirks may limit near‑term upside: AbbVie trades below its 50‑ and 200‑day moving averages and shows a high reported P/E (~86.8) and a negative ROE figure (accounting effect), factors that can pressure sentiment and constrain multiple expansion until growth visibility improves. MarketBeat ABBV snapshot

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ABBV shares. Royal Bank Of Canada began coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Trading Down 0.0%

NYSE:ABBV opened at $204.86 on Wednesday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a 50-day moving average of $222.48 and a 200-day moving average of $224.74. The firm has a market cap of $362.23 billion, a price-to-earnings ratio of 86.81, a price-to-earnings-growth ratio of 0.71 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.